Evidence map›Paper›PMID 39656241›Full record

ArticleArchives of toxicology2025

Impact of administration routes and dose frequency on the toxicology of SARS-CoV-2 mRNA vaccines in mice model.

Jae-Hun Ahn, Jisun Lee, Gahyun Roh, Na-Young Lee, Hee-Jin Bae, Euna Kwon, Kang-Min Han, Ji-Eun Kim, Hyo-Jung Park, Soyeon Yoo and 5 more

Abstract read
In one paragraph

Article in Archives of toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jae-Hun Ahn *Department of Experiment Animal Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Jisun Lee *Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Republic of Korea.
Gahyun Roh *Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Republic of Korea.
Na-Young LeeDepartment of Experiment Animal Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Hee-Jin BaeDepartment of Experiment Animal Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Euna KwonDepartment of Experiment Animal Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Kang-Min HanGraduate School of Translational Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Ji-Eun KimDepartment of Experiment Animal Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Hyo-Jung ParkDepartment of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Republic of Korea.
Soyeon YooCenter for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea.
Sung Pil KwonCenter for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea.
Eun-Kyoung BangCenter for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea.
Gyochang KeumCenter for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea.
Jae-Hwan NamDepartment of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Republic of Korea. jhnam@catholic.ac.kr.
Byeong-Cheol KangDepartment of Experiment Animal Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea. bckang@snu.ac.kr.ORCID 0000-0002-9485-516X

Funding

Ministry of Food and Drug Safety 22213MFDS421
6 · The paper itself

Abstract

The increasing use of SARS-CoV-2 mRNA vaccines has raised concerns about their potential toxicological effects, necessitating further investigation to ensure their safety. To address this issue, we aimed to evaluate the toxicological effects of SARS-CoV-2 mRNA vaccine candidates formulated with four different types of lipid nanoparticles in ICR mice, focusing on repeated doses and administration routes. We conducted an extensive analysis in which mice received the mRNA vaccine candidates intramuscularly (50 μg/head) twice at 2-week intervals, followed by necropsy at 2 and 14 dpsi (days post-secondary injection). In addition, we performed a repeated dose toxicity test involving three, four, or five doses and compared the toxicological outcomes between intravenous and intramuscular routes. Our findings revealed that all vaccine candidates significantly induced SARS-CoV-2 spike protein-specific IgG and T cell responses. However, at 2 dpsi, there was a notable temporary decrease in lymphocyte and reticulocyte counts, anemia-related parameters, and significant increases in cardiac damage markers, troponin-I and NT-proBNP. Histopathological analysis revealed severe inflammation and necrosis at the injection site, decreased erythroid cells in bone marrow, cortical atrophy of the thymus, and increased spleen cellularity. While most toxicological changes observed at 2 dpsi had resolved by 14 dpsi, spleen enlargement and injection site damage persisted. Furthermore, repeated doses led to the accumulation of toxicity, and different administration routes resulted in distinct toxicological phenotypes. These findings highlight the potential toxicological risks associated with mRNA vaccines, emphasizing the necessity to carefully consider administration routes and dosage regimens in vaccine safety evaluations, particularly given the presence of bone marrow and immune organ toxicity, which, though eventually reversible, remains a serious concern.

Indexed as

COVID-19COVID-19 VaccinesSARS-CoV-2AnimalsAntibodies, ViralDose-Response Relationship, DrugFemaleImmunoglobulin GInjections, IntramuscularLiposomesMaleMiceMice, Inbred ICRmRNA VaccinesNanoparticlesSpike Glycoprotein, CoronavirusAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GLipid NanoparticlesLiposomesmRNA VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, SyntheticLipid nanoparticlemRNA vaccineSafetySARS-CoV-2Toxicity

Identifiers

PMID39656241
PMCPMC11775000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.